本文選題：乙型肝炎 + 阿德福韋酯��； 參考：《臨床醫(yī)學(xué)研究與實(shí)踐》2016年21期

【摘要】：目的研究和觀察阿德福韋酯聯(lián)合苦參素膠囊治療慢性乙型肝炎(CHB)肝硬化患者的療效及對(duì)患者DNA載量(HBVDNA)的影響。方法隨機(jī)選取180例CHB肝硬化患者作為研究對(duì)象,依據(jù)治療方式的不同分為單一用藥的對(duì)照組(90例)和聯(lián)合用藥組(90例),其中對(duì)照組給予阿德福韋酯治療,聯(lián)合用藥組給予阿德福聯(lián)合苦參素膠囊治療。所有患者均以48周為1個(gè)療程,比較兩組患者的疾病轉(zhuǎn)歸及對(duì)HBV-DNA的影響。結(jié)果治療后ALT、TBIL復(fù)常率及HBeAg轉(zhuǎn)陰率,兩組比較差異具有統(tǒng)計(jì)學(xué)意義(P0.05),但HBeAg/HBeAb血清轉(zhuǎn)換組間比較差異不明顯(P0.05)。隨著治療的進(jìn)行,兩組患者的HBVDNA含量呈下降趨勢(shì),HBV-DNA轉(zhuǎn)陰率呈上升趨勢(shì),第12、24周,聯(lián)合用藥組在HBV-DNA含量及轉(zhuǎn)陰率上顯著優(yōu)于對(duì)照組,差異具有統(tǒng)計(jì)學(xué)意義(P0.05),第36、48周組間比較HBV-DNA含量及轉(zhuǎn)陰率差異無統(tǒng)計(jì)學(xué)意義(P0.05)。經(jīng)治療,兩組患者肝纖維化各指標(biāo)較治療前均有改善(P0.05)。聯(lián)合用藥組在LN、PC-Ⅲ及Ⅳ-C指標(biāo)上改善程度與對(duì)照組相比,差異具有統(tǒng)計(jì)學(xué)意義(P0.05),但HA指標(biāo)比較無明顯差異(P0.05)。結(jié)論阿德福韋酯聯(lián)合苦參素膠囊能夠抑制乙肝病毒復(fù)制,降低HBV-DNA含量,防止肝細(xì)胞損傷及肝纖維產(chǎn)生,療效顯著,值得臨床推廣運(yùn)用。
[Abstract]:Objective to study the efficacy of adefovir ester combined with matrine capsule in the treatment of chronic hepatitis B (CHB) patients with liver cirrhosis and the effect of adefovir ester combined with matrine capsule on the DNA load and HBV DNA in patients with chronic hepatitis B (CHB). Methods one hundred and eighty patients with CHB cirrhosis were randomly divided into control group (n = 90) and combined group (n = 90). The control group was treated with adefovir dipivoxil. The combined drug group was treated with adrofol combined with matrine capsule. All patients were treated with 48 weeks as a course of treatment. The outcome of the disease and the effect on HBV-DNA were compared between the two groups. Results there was a significant difference between the two groups in the recovery rate of TBIL and the negative rate of HBeAg after treatment, but there was no significant difference between the two groups in HBeAg/HBeAb seroconversion group (P 0.05). With the progress of treatment, the HBVDNA content of the two groups showed a downward trend and the negative rate of HBV-DNA increased. At the 12th week, the HBV-DNA content and the negative conversion rate in the combined treatment group were significantly better than those in the control group, and the positive rate of HBV-DNA in the combined treatment group was significantly higher than that in the control group. The difference was statistically significant (P 0.05). There was no significant difference in the content of HBV-DNA and the rate of negative conversion between the three groups at week 36 (P 0.05). After treatment, each index of hepatic fibrosis in both groups was improved compared with that before treatment. Compared with the control group, the improvement degree of LNN PC- 鈪，

本文編號(hào)：1890083